Gilead Sciences, Inc. (GILD)

FY2025 revenue grew ~6% to ~$29B, driven by Biktarvy growth and early lenacapavir contributions. This is above pharma average but trails biotech growth leaders. Excluding Veklury (COVID) decline, underlying growth is 8-9%, which is respectable for a large-cap biopharma.

Biktarvy's HIV treatment market share exceeds 45% and is still growing as it takes share from older regimens. In HIV PrEP, lenacapavir's Phase 3 results (100% efficacy in PURPOSE trials) position it to dominate the $10B+ prevention market. Oncology share is growing but from a small base.

HIV drug pricing is politically sensitive but Gilead has maintained pricing discipline with modest annual increases. Lenacapavir pricing will be critical — the company has committed to accessible pricing in low-income countries but can command premium pricing in developed markets. IRA drug pricing negotiation is a headwind for Biktarvy.

Lenacapavir PrEP is Gilead's most important product launch in a decade. Trodelvy label expansions have been slower than hoped. Cell therapy (Yescarta) is growing but the space is intensely competitive. The pipeline outside HIV is decent but not deep compared to peers like AbbVie or Merck.

HIV patients on Biktarvy have very high switching costs — changing antiretroviral regimens risks viral rebound, new resistance mutations, and side effects. Physicians are reluctant to switch patients off a working regimen. This creates annuity-like retention. In oncology, switching costs are lower as treatment protocols evolve frequently.

Pharma has minimal network effects. Gilead's HIV treatment guidelines influence is a form of 'standard of care' lock-in, but this is expertise-based rather than network-driven. Clinical trial data generates positive feedback loops for regulatory approvals.

Biktarvy patents extend through 2033 (with pediatric exclusivity). Lenacapavir's novel mechanism of action and complex manufacturing provide additional protection. Gilead's regulatory relationships with FDA and global health agencies (WHO, PEPFAR) are deep. The IRA's drug pricing negotiation introduces a new form of regulatory risk.

Gilead generates 40%+ operating margins and $8B+ in annual free cash flow, providing massive resources for R&D and acquisitions. The HIV franchise produces cash with minimal marginal cost, funding pipeline development. Manufacturing complexity for biologics (cell therapy, long-acting injectables) creates barriers for generics.

FY2026 EPS estimates have been revised up ~10% as lenacapavir launch expectations firm up. The Street is modeling a step-change in growth from 2026 onward. Long-term revenue estimates now include $5B+ in lenacapavir peak sales, which is driving positive revisions.

Lenacapavir PURPOSE trial results (100% efficacy for HIV prevention) generated extraordinary positive sentiment. However, the narrative is complex: pricing debates, global access commitments, and the question of whether health systems will fund widespread PrEP create uncertainty about peak sales achievability.

CEO Daniel O'Day has been criticized for underwhelming M&A (Immunomedics/Trodelvy at $21B was expensive given subsequent label expansion struggles). Capital allocation has been a mixed bag — the dividend is well-covered and buybacks are consistent, but the company hasn't made a transformative acquisition to diversify beyond HIV. Pipeline execution in oncology needs improvement.